<DOC>
	<DOCNO>NCT00233610</DOCNO>
	<brief_summary>The aim study investigate efficacy different dose schedule Nolvadex prevent gynecomastia/mastalgia induce Casodex 150 mg monotherapy patient prostate cancer .</brief_summary>
	<brief_title>Two Different Regimens Nolvadex Preventing Gynecomastia Induced Casodex 150 mg Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gynecomastia</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically confirm prostate cancer Locally advance prostate cancer patient suitable Casodex 150 mg monotherapy Age &gt; 75 yr No metastatic disease ( M1 ) . No presence gynaecomastia and/or mastalgia screen No therapy medication able provoke gynaecomastia and/or mastalgia within 6 month trial entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Casodex monotherapy</keyword>
</DOC>